1. Wang B, Yang J, Cao S, Wang H, Pan X, Zhu J, et al. Preparation of specific anti-Helicobacter pylori yolk antibodies and their antibacterial effects. Int J Clin Exp Pathol 2014; 7: 6430-6437.
2. Suarez G, Reyes VE, Beswick EJ. Immune response to H. pylori. World J Gastroenterol 2006; 12: 5593-5598.
3. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 2018; 155: 1372-1382. e17.
4. Ansari S, Yamaoka Y. Helicobacter pylori virulence factors exploiting gastric colonization and its pathogenicity. Toxins (Basel) 2019; 11: 677.
5. Ghasemi-Kebria F, Ghaemi E, Azadfar S, Roshandel G. Epidemiology of Helicobacter pylori infection among Iranian children. Arab J Gastroenterol 2013; 14: 169-172.
6. Eshraghian A. Epidemiology of Helicobacter pylori infection among the healthy population in Iran and countries of the Eastern Mediterranean Region: a systematic review of prevalence and risk factors. World J Gastroenterol 2014; 20: 17618-17625.
7. Ansari S, Yamaoka Y. Helicobacter pylori infection, its laboratory diagnosis, and antimicrobial resistance: a perspective of clinical relevance. Clin Microbiol Rev 2022; 35(3): e0025821.
8. Wang Z, Han W, Xue F, Zhao Y, Wu P, Chen Y, et al. Nationwide gastric cancer prevention in China, 2021-2035: a decision analysis on effect, affordability and cost-effectiveness optimisation. Gut 2022; 71: 2391-2400.
9. Yousefi-Avarvand A, Vaez H, Tafaghodi M, Sahebkar AH, Arzanlou M, Khademi F. Antibiotic resistance of Helicobacter pylori in Iranian children: a systematic review and meta-analysis. Microb Drug Resist 2018; 24: 980-986.
10. Khademi F, Sahebkar A. An updated systematic review and meta-analysis on the Helicobacter pylori antibiotic resistance in Iran (2010–2020). Microb Drug Resist 2020; 26: 1186-1194.
11. Khademi F, Sahebkar AH, Vaez H, Arzanlou M, Peeridogaheh H. Characterization of clarithromycin-resistant Helicobacter pylori strains in Iran: A systematic review and meta-analysis. J Glob Antimicrob Resist 2017; 10: 171-178.
12. Nomura S, Suzuki H, Masaoka T, Kurabayashi K, Ishii H, Kitajima M, et al. Effect of dietary anti‐urease immunoglobulin Y on Helicobacter pylori infection in Mongolian gerbils. Helicobacter 2005; 10: 43-52.
13. Pereira EPV, Van Tilburg MF, Florean EOPT, Guedes MIF. Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review. Int Immunopharmacol 2019; 73: 293-303.
14. Borhani K, Mobarez AM, Khabiri AR, Behmanesh M, Khoramabadi N. Production of specific IgY Helicobacter pylori recombinant OipA protein and assessment of its inhibitory effects towards attachment of H. pylori to AGS cell line. Clin Exp Vaccine Res 2015; 4: 177-183.
15. Suzuki H, Nomura S, Masaoka T, Goshima H, Kamata N, Kodama Y, et al. Effect of dietary anti‐Helicobacter pylori‐urease immunoglobulin Y on Helicobacter pylori infection. Aliment Pharmacol Ther 2004; 20 Suppl 1: 185-192.
16. Cheng S, Li H, Luo J, Chi J, Zhao W, Lin J, et al. Egg yolk antibody combined with bismuth-based quadruple therapy in Helicobacter pylori infection rescue treatment: a single-center, randomized, controlled study. Front Microbiol 2023; 14: 1150129.
17. Borhani K, Mohabati Mobarez A, Khabiri AR, Behmanesh M, Khoramabadi N. Inhibitory effects of rHP-NAP IgY against Helicobacter pylori attachment to AGS cell line. Microb Pathog 2016; 97: 231-235.
18. Mony TJ, Kwon H-S, Won M-K, Kang YM, Lee S-H, Kim S-Y, et al. Anti-urease immunoglobulin (IgY) from egg yolk prevents Helicobacter pylori infection in a mouse model. Food Agric Immunol 2019; 30: 662-676.
19. Leiva CL, Gallardo MJ, Casanova N, Terzolo H, Chacana P. IgY-technology (egg yolk antibodies) in human medicine: A review of patents and clinical trials. Int Immunopharmacol 2020; 81: 106269.
20. Kovacs-Nolan J, Mine Y. Egg yolk antibodies for passive immunity. Annu Rev Food Sci Technol 2012; 3: 163-182.
21. Mine Y, Kovacs-Nolan J. Chicken egg yolk antibodies as therapeutics in enteric infectious disease: a review. J Med Food 2002; 5: 159-169.
22. Müller S, Schubert A, Zajac J, Dyck T, Oelkrug C. IgY antibodies in human nutrition for disease prevention. Nutr J 2015; 14: 109.
23. Do LH, Vi TT, Le HT, Do TM, Do DK, Nguyen DD, et al. The inhibitory effect of anti-urease IgY on Helicobacter pylori infection in Swiss albino mice. Pharm Sci Asia 2021; 48: 255-268.
24. Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20: 1450-1469.
25. Malekshahi ZV, Gargari SL, Rasooli I, Ebrahimizadeh W. Treatment of Helicobacter pylori infection in mice with oral administration of egg yolk-driven anti-UreC immunoglobulin. Microb Pathog 2011; 51: 366-372.
26. Shin JH, Yang M, Nam SW, Kim JT, Myung NH, Bang WG, et al. Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection. Clin Diagn Lab Immun 2002; 9: 1061-1066.
27. Shin J-H, Roe I-H, Kim H-G. Production of anti-Helicobacter pylori urease-specific immunoglobulin in egg yolk using an antigenic epitope of H. pylori urease. J Med Microbiol 2004; 53: 31-34.
28. Hong KS, Ki MR, Ullah HMA, Lee EJ, Kim YD, Chung MJ, et al. Preventive effect of anti-VacA egg yolk immunoglobulin (IgY) on Helicobacter pylori-infected mice. Vaccine 2018; 36: 371-380.